Global Innovation Index 2019: Switzerland is the world’s most-innovative country

Wednesday, July 24, 2019 @ 12:00 am

Switzerland is the world’s most-innovative country followed by Sweden, the United States of America (U.S.), the Netherlands and the United Kingdom (U.K.), according to the 2019 edition of the Global Innovation Index (GII), which also identifies regional leaders India, South Africa, Chile, Israel and Singapore, with China, Viet Nam and Rwanda topping their income groups.

Now in its 12th edition, the GII is a global benchmark that helps policy makers better understand how to stimulate and measure innovative activity, a main driver of economic and social development. The GII 2019 ranks 129 economies based on 80 indicators, from traditional measurements like research and development investments and international patent and trademark applications to newer indicators including mobile-phone app creation and high-tech exports.

The GII 2019 also looks at the economic context: Despite signs of slowing economic growth, innovation continues to blossom, particularly in Asia, but pressures are looming from trade disruptions and protectionism. Sound government planning for innovation is critical for success, the report shows.

“The GII shows us that countries that prioritize innovation in their policies have seen significant increases in their rankings,” said WIPO Director General Francis Gurry. “The rise in the GII by economic powerhouses like China and India have transformed the geography of innovation and this reflects deliberate policy action to promote innovation,” said WIPO Director General Francis Gurry.

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Nouscom: Patient enrollment of study for metastatic colorectal cancer completed

Primary efficacy endpoint readout expected in mid-2025 Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses and durable tumor shrinkage NOUS-209 is being evaluated in multiple clinical studies targeting MSI cancers, from early-stage cancer interception through to metastatic disease
November 19, 2024

InSphero awarded major EU grant for diversity in 3D in vitro testing

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.
November 18, 2024

Ymmunobio honored with 3rd place at the Prix Galien USA Awards

Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.
November 15, 2024

Pharvaris: 3rd quarter 2024 financial results and business updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the
November 13, 2024

Aurealis Therapeutics: CHF 8M for chronic wounds studies and oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.
November 13, 2024